KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 2643 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study. PMID 39410009 · Cancers (Basel) · 2024-Oct-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 2 Figure · 2 Panel · risk not_visible
Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer. PMID 39418020 · JAMA Netw Open · 2024-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 8 Panel · risk visible
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. PMID 38913881 · J Natl Cancer Inst · 2024-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis. PMID 38885371 · J Natl Cancer Inst · 2024-Oct-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial. PMID 38652147 · Int J Surg · 2024-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 3 Panel · risk unclear
Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial. PMID 38631536 · Int J Radiat Oncol Biol Phys · 2024-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial. PMID 38387811 · Int J Radiat Oncol Biol Phys · 2024-Oct-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial. PMID 39461775 · ESMO Open · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 5 Figure · 10 Panel · risk visible
Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial). PMID 39461773 · ESMO Open · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT. PMID 39435271 · Liver Cancer · 2024-Oct 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 4 Panel · risk visible
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study. PMID 39435268 · Liver Cancer · 2024-Oct 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 6 Figure · 6 Panel · risk visible
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for initially unresectable locally advanced colon cancer: short-term outcomes of an open-label, single-centre, randomised, controlled, phase 3 trial. PMID 39364270 · EClinicalMedicine · 2024-Oct 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 3 Panel · risk visible
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. PMID 39306923 · Lung Cancer · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. PMID 39265613 · Lancet Haematol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial. PMID 39265599 · Lancet Respir Med · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial. PMID 39221992 · Cancer Commun (Lond) · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 1 Panel · risk visible
The significance of consolidation chemotherapy after concurrent chemoradiotherapy in esophageal squamous cell carcinoma: a randomized controlled phase III clinical trial. PMID 39199003 · Thorac Cancer · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 3 Figure · 12 Panel · risk not_visible
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. PMID 39167741 · J Clin Oncol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration. PMID 39152324 · Leukemia · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
S B
严格 v3 独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. PMID 39146944 · Lancet Respir Med · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG). PMID 39080350 · Br J Cancer · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 4 Figure · 6 Panel · risk visible
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial. PMID 39067465 · Lancet Haematol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. PMID 39066879 · Qual Life Res · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. PMID 38992123 · Nat Med · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 2 Panel · risk visible
A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma. PMID 38990441 · Esophagus · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. PMID 38986769 · Ann Oncol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. PMID 38964714 · Ann Oncol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE. PMID 38888616 · Ann Hematol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study. PMID 38849283 · Clin Lymphoma Myeloma Leuk · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC. PMID 38729426 · J Thorac Oncol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. PMID 38523017 · Eur Urol Oncol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. PMID 39609425 · Blood Cancer J · 2024-Nov-28 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 3 Figure · 7 Panel · risk unclear
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. PMID 39602630 · N Engl J Med · 2024-Nov-28 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. PMID 39282906 · N Engl J Med · 2024-Nov-28 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study. PMID 39608979 · J Immunother Cancer · 2024-Nov-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 6 Panel · risk unclear
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. PMID 39580202 · Lancet · 2024-Nov-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. PMID 39547252 · Lancet · 2024-Nov-23 The record describes a randomized, open-label clinical trial in human oncology patients. It is a phase II/III trial (SU2C-SARC032) with a drug intervention (pembrolizumab) and reports formal primary efficacy results for disease-free survival (a time-to-event endpoint) with hazard ratio and Kaplan-Meier analysis. The trial is not post-hoc, subgroup, or safety-only. All required criteria are explicitly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 8 Figure · 11 Panel · risk visible
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). PMID 39186709 · J Clin Oncol · 2024-Nov-20 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. PMID 39550172 · Lancet · 2024-Nov-16 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. PMID 39248780 · Clin Cancer Res · 2024-Nov-15 The record is an FDA approval summary for belzutifan, reporting primary results from the definitive Phase III LITESPARK-005 trial. All required criteria are explicitly established: oncology (renal cell carcinoma), human, randomized, Phase III (definitive), time-to-event efficacy endpoint (PFS), drug intervention (belzutifan), and original trial result. The report type is primary (initial results of the trial).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. PMID 39282910 · N Engl J Med · 2024-Nov-14 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Preoperative Chemoradiotherapy for Resectable Gastric Cancer. PMID 39282905 · N Engl J Med · 2024-Nov-14 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial. PMID 39532849 · Signal Transduct Target Ther · 2024-Nov-13 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 6 Panel · risk unclear
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. PMID 38899716 · N Engl J Med · 2024-Nov-07 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. PMID 38828984 · N Engl J Med · 2024-Nov-07 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11). PMID 39164041 · Int J Gynecol Cancer · 2024-Nov-04 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE). PMID 38941345 · Jpn J Clin Oncol · 2024-Nov-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. PMID 39230571 · Clin Cancer Res · 2024-Nov-01 The record describes a randomized Phase III trial (EV-302/KEYNOTE-A39) with drug interventions and primary time-to-event endpoints (PFS and OS) reported as formal results for FDA approval, meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study. PMID 38956837 · Int J Cancer · 2024-Nov-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Clinical Benefits of new Systemic Therapy for Small-Cell Lung Cancer Over Two Decades: A Cross-Sectional Study. PMID 39476816 · Clin Respir J · 2024-Nov 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable